Randomized trial · people
Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, adding afamelanotide to UV-B light brought color back to vitiligo patches faster and more fully than light alone, mainly in darker skin types.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2015
- Journal
- JAMA Dermatol
What they tested
Does adding an afamelanotide implant to narrowband UV-B light therapy work better and stay safe for widespread vitiligo, compared with the light therapy alone?
How the study was done
A randomized trial at 3 dermatology sites in adults with nonsegmental vitiligo covering 15% to 50% of the body and skin types III to VI. After 1 month of narrowband UV-B light, 28 people also got a 16 mg afamelanotide implant under the skin once a month for 4 months, while 27 stayed on UV-B light alone.

What they found
By day 56, people getting both treatments had a statistically significant better response than those on light alone. More people in the combined group regained color on the face and upper extremities, and they did so sooner: 41.0 vs 61.0 days for the face and 46.0 vs 69.0 days for the upper extremities. At day 168, repigmentation (color returning to pale patches) was 48.64% with the combination vs 33.26% with light alone. The gain showed up in skin types IV to VI but not in skin type III; both groups had skin redness, and the combined group also had nausea and minor infections.
What it doesn’t show
This was a small trial, with 28 and 27 people in the two groups, and afamelanotide was given for only 4 months. It tested afamelanotide only together with UV-B light, not on its own, and the benefit was not significant in lighter skin type III.
The paper
Lim et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015.
The compound
More studies on Melanotan I
- Melanotan I: more pain-free sun time in protoporphyria trialsRandomized trial · people · 2015
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Melanotan II: melanoma diagnosed in a 20-year-old woman after useObservational study · people · 2014
- Every study on Melanotan I
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.